1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
629E9F246D5535988852573EC00777AEB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/the-role-of-market-research-in-the-reporting-of-adverse-events-by-third-party-vendors?opendocument
18
19opendocument
2034.235.143.190
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing Market Research Managing Market Research Processes

The Role of Market Research in the Reporting of Adverse Events by Third-Party Vendors

DB Image

ID: 4992


Features:

Metrics


Pages/Slides: 38


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"The Role of Market Research in the Reporting of Adverse Events by Third-Party Vendors"


Study Overview

As the U.S. Food and Drug Administration sharpens its focus on safety, there is more attention on post-market surveillance of products through adverse event (AE) reporting. This benchmarking study examines market research’s role in reporting adverse events uncovered by third-party vendors, in particular those in market research and analytics roles.
The study data and findings provide insight to market research and business intelligence executives and managers about how the pharmaceutical industry applies FDA regulations that require pharmaceutical manufacturers to be responsible for reporting adverse events relating to their drugs on market. The study includes FDA regulations surrouding AE reporting and information from a Best Practices, LLC interview with an FDA compliance officer.

Key Topics

  • Reporting Requirements for Market Research and Vendors
  • Working with Third-Party Vendors on AE Collection
  • Physician Guidance & Support
  • Impact of Vendor Reporting
Key Metrics
  • Company operations with SOPs for Adverse Event (AE) Collection
  • Market Research’s AE Reporting Protocol
  • Vendor AE Reporting Protocol
  • Group Responsible for AE Collection
  • How Vendors Report AEs
  • What Company Groups do Vendors Report AEs to
  • Percentage of AEs from Vendors
  • Percentage of AEs Expected from Vendors in next year
  • How Vendors Train for AE Collection
  • Vendor Support for AE Collection
  • Opinion on Vendor AE Collection/Reporting
  • Reporting Guidance for Physicians Participating in Vendor Market Research
  • Whether Physicians Compensated for Market Research Participation
  • Does Physician Compensation Compromise AE reporting?
  • Impact of AE Reporting by Physicians in Market Research Studies
  • Risk of Misreporting Physician Comments by Vendors
  • Impact of Requiring Vendor Collection of AEs
Key Findings
  • While the FDA has stated that any company representative who has the potential to collect AEs from physicians and patients is required to report such data, the industry seems divided on what to do. About half the benchmark partners have taken steps to have third-party vendors collect AEs while the other half has not.
  • All the partners report that less than 5 percent of their adverse events reports come from third-party market research vendors. Only one company expected an increase in reporting to 6-10 percent in the next year.
Methodology

This research was conducted on behalf of one of Best Practices, LLC’s Business Excellence Board (BEB) clients in the pharmaceutical industry and was based on survey results from 14 participants from 13 pharma companies. Findings also were based on interviews with several participants.

Industries Profiled:
Pharmaceutical; Biotech; Chemical; Medical Device


Companies Profiled:
Abbott Laboratories; EMD Serono; Alcon; Amgen; AstraZeneca; Amylin; Biogen Idec; Boehringer Ingelheim; Eli Lilly and Company; Genentech; Ortho-McNeil; Roche; Sanofi-aventis


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.